Financing, Equity Capital Markets

I-Mab Biopharma

02/21
|
$203.9 Million
Piper Sandler served as bookrunner for I-MAB Biopharma on a follow-on offering
Sub-Type
Follow-On Offering
Sub-Sector
Biopharma